Respiratory Syncytial Virus Prevention: A New Era of Vaccines

Respiratory syncytial virus (RSV) is a pathogen that primarily affects the respiratory system, leading to upper and lower tract infections. Children, individuals aged 60 above, with impaired immune systems are more susceptible developing RSV infections (LRTIs), which can result in fatalities some instances. Symptoms of LRTI include shortness breath, wheezing, pneumonia, bronchiolitis. Current management RSV-LRTI includes conservative symptomatic treatment. The Food Drug Administration (FDA) recently approved two vaccines effectively prevent acute severe requiring hospitalizations. Nirsevimab (Beyfortus) for infants born at 35 weeks gestation above. At same time, RSVPreF3 OA (Arexvy) recommended adults older. Both effective against major strains require single doses induce immunity. In this article, we will discuss mechanism action, effectiveness, side effects these novel their possible impact.